Legal status in the United States
Is GHRP-6 legal?
Read at FDA, DEA and WADAPublished by PepVault
GHRP-6 has no FDA-approved product, is not a federally controlled substance, and is banned in sport (WADA names it under S2.2.4), as of November 18, 2026.
GHRP-6 at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Not approved |
| Compounding | Safety-risk list for outsourcing facilities (503B category 2) |
| DEA schedule | Not controlled |
| Sport (WADA) | Banned, named (S2.2.4) |
FDA approval
GHRP-6 has no FDA-approved product: Drugs@FDA lists no application for it.
- Drugs@FDA data (openFDA): applications listing “GHRP” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
FDA keeps GHRP-6 in 503B category 2 (outsourcing facilities) since September 29, 2023: bulk substances that may raise significant safety risks. For pharmacies it sits in 503A category 3, substances nominated without adequate support.
The source: “Growth hormone releasing peptide-6 (GHRP-6)”
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA bans GHRP-6 at all times, in and out of competition: the 2026 list names it among the GH-releasing peptides under S2.2.4.
The source: “GHRP-6”
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
How it is sold when it isn’t approved
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.
The source: falsely labeled “for research purposes” or “not for human consumption.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about GHRP-6 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is GHRP-6 FDA approved?
GHRP-6 has no FDA-approved product: Drugs@FDA lists no application for it.
Is GHRP-6 a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is GHRP-6 banned in sport?
WADA bans GHRP-6 at all times, in and out of competition: the 2026 list names it among the GH-releasing peptides under S2.2.4.
What does FDA say about compounding GHRP-6?
FDA keeps GHRP-6 in 503B category 2 (outsourcing facilities) since September 29, 2023: bulk substances that may raise significant safety risks. For pharmacies it sits in 503A category 3, substances nominated without adequate support.
What does FDA say about the “research use only” label?
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.